A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha V beta 3 integrin, ± dacarbazine in patients with metastatic melanoma

Trial Profile

A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha V beta 3 integrin, ± dacarbazine in patients with metastatic melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2010

At a glance

  • Drugs Dacarbazine; Etaracizumab
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2010 Primary endpoint 'Time to disease progression' has not been met.
    • 27 Jan 2010 Primary endpoint 'Objective clinical response rate' has not been met.
    • 27 Jan 2010 Primary endpoint 'Disease progression rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top